BioLineRx Responds to Rumors, Cooling Off Its Share Price

Speculation about its new anti-schizophrenia drug fed 90% spike; company officials state that they have no new information.

Yoram Gabison
Yoram Gabison
Send in e-mailSend in e-mail
Yoram Gabison
Yoram Gabison

Comments